Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Australia
0
South Africa
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. (21r)-argatroban
2. (21r)-argatroban Anhydrous
3. (21s)-argatroban
4. (21s)-argatroban Anhydrous
5. (2r,4r)-1-((2s)-5-((aminoiminomethyl)amino)-1-oxo-2-((((3r)-1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic Acid
6. (2r,4r)-1-((2s)-5-((aminoiminomethyl)amino)-1-oxo-2-((((3s)-1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic Acid
7. (2r,4r)-1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic Acid
8. (2r,4r)-1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic Acid Monohydrate
9. Acova
10. Argatroban
11. Argatroban Anhydrous
12. Argatroban Hydrate
13. Argatroban Monohydrate
14. Mci 9038
15. Mci-9038
16. Md 805
17. Md-805
18. Md805
19. Mmtqap
20. Mpqa
21. Novastan
1. (21r)-argatroban
2. 121785-71-5
3. 0dw7mih1vx
4. (2r,4r)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(3r)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic Acid
5. Dsstox_cid_26467
6. Dsstox_rid_81640
7. Dsstox_gsid_46467
8. Cas-74863-84-6
9. Unii-0dw7mih1vx
10. Ncgc00164592-01
11. 21(r)-argatroban
12. Schembl4375
13. Bidd:gt0748
14. Chembl59461
15. 21r-argatroban Anhydrous
16. Argatroban Anhydrous, 21r-
17. Ex-a4205
18. Zinc3807172
19. Tox21_112218
20. Tox21_112218_1
21. Argatroban Anhydrous, (21r)-
22. Ncgc00166413-02
23. 2-piperidinecarboxylic Acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-, (2r-(1(s*(r*)),2alpha,4beta))-
24. Q474880
| Molecular Weight | 508.6 g/mol |
|---|---|
| Molecular Formula | C23H36N6O5S |
| XLogP3 | 1.3 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 9 |
| Exact Mass | 508.24678944 g/mol |
| Monoisotopic Mass | 508.24678944 g/mol |
| Topological Polar Surface Area | 189 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 887 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Argatroban |
| PubMed Health | Argatroban (Injection) |
| Drug Classes | Anticoagulant |
| Drug Label | Argatroban is a synthetic direct thrombin inhibitor and the chemical name is 1-[5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, monohydrate. Argatroban has... |
| Active Ingredient | Argatroban |
| Dosage Form | Injectable |
| Route | injection; Injection |
| Strength | 250mg/250ml; 100mg; 250mg/2.5ml (100mg/ml) |
| Market Status | Tentative Approval; Prescription |
| Company | Par Sterile Products; Baxter Hlthcare; Mylan Institutional; Pliva Hrvatska Doo; Hikma Pharm |
| 2 of 2 | |
|---|---|
| Drug Name | Argatroban |
| PubMed Health | Argatroban (Injection) |
| Drug Classes | Anticoagulant |
| Drug Label | Argatroban is a synthetic direct thrombin inhibitor and the chemical name is 1-[5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, monohydrate. Argatroban has... |
| Active Ingredient | Argatroban |
| Dosage Form | Injectable |
| Route | injection; Injection |
| Strength | 250mg/250ml; 100mg; 250mg/2.5ml (100mg/ml) |
| Market Status | Tentative Approval; Prescription |
| Company | Par Sterile Products; Baxter Hlthcare; Mylan Institutional; Pliva Hrvatska Doo; Hikma Pharm |
Antithrombins
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. (See all compounds classified as Antithrombins.)
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25765
Submission : 2012-03-19
Status : Active
Type : II
NDC Package Code : 14593-851
Start Marketing Date : 2023-12-22
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-10-05
Pay. Date : 2013-09-26
DMF Number : 21304
Submission : 2008-01-30
Status : Active
Type : II
NDC Package Code : 45562-1124
Start Marketing Date : 2005-12-14
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-12
Pay. Date : 2013-03-26
DMF Number : 25400
Submission : 2011-10-27
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2014-12-15
Pay. Date : 2014-11-28
DMF Number : 28030
Submission : 2014-05-15
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42426
Submission : 2025-08-15
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2021-10-01
Pay. Date : 2021-04-14
DMF Number : 35491
Submission : 2020-12-26
Status : Active
Type : II
Registration Number : 305MF10140
Registrant's Address : Building C25-C28, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
Initial Date of Registration : 2023-12-22
Latest Date of Registration :
NDC Package Code : 62227-015
Start Marketing Date : 2018-01-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (2kg/2kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Otran Korea Co., Ltd.
Registration Date : 2025-04-30
Registration Number : 20250430-210-J-1853
Manufacturer Name : BrightGene Pharmaceutical Co.,Ltd.
Manufacturer Address : Building C25-C28, No.218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-11-18
Pay. Date : 2013-10-25
DMF Number : 20760
Submission : 2007-08-07
Status : Active
Type : II
NDC Package Code : 55486-1607
Start Marketing Date : 2015-03-23
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25893
Submission : 2012-02-20
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31131
Submission : 2016-12-05
Status : Active
Type : II
NDC Package Code : 17223-0003
Start Marketing Date : 2014-07-16
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7801
Submission : 1988-12-08
Status : Inactive
Type : II
Registrant Name : Tanabe Pharma Korea Co., Ltd.
Registration Date : 2022-01-21
Registration Number : 20220121-210-J-1219
Manufacturer Name : Mitsubishi Tanabe Pharma Factory Ltd., Onoda Plant
Manufacturer Address : 7473-2, Ooaza Onoda, SanyoOnoda,Yamaguchi, 756-0054, Japan

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25893
Submission : 2012-02-20
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2021-10-01
Pay. Date : 2021-04-14
DMF Number : 35491
Submission : 2020-12-26
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-11-18
Pay. Date : 2013-10-25
DMF Number : 20760
Submission : 2007-08-07
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25765
Submission : 2012-03-19
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2014-12-15
Pay. Date : 2014-11-28
DMF Number : 28030
Submission : 2014-05-15
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-07-12
Pay. Date : 2013-03-26
DMF Number : 25400
Submission : 2011-10-27
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-10-05
Pay. Date : 2013-09-26
DMF Number : 21304
Submission : 2008-01-30
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7801
Submission : 1988-12-08
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22935
Submission : 2009-07-10
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31131
Submission : 2016-12-05
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registration Number : 304MF10018
Registrant's Address : Building C25-C28, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China...
Initial Date of Registration : 2022-01-26
Latest Date of Registration : 2022-01-26

Registration Number : 230MF10028
Registrant's Address : Building C25-C28, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China...
Initial Date of Registration : 2018-02-15
Latest Date of Registration : 2021-03-05

Registration Number : 305MF10140
Registrant's Address : Building C25-C28, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China...
Initial Date of Registration : 2023-12-22
Latest Date of Registration : 2023-12-22

Registration Number : 302MF10033
Registrant's Address : Building C25-C28, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China...
Initial Date of Registration : 2020-03-02
Latest Date of Registration : 2021-08-20

Registration Number : 218MF10153
Registrant's Address : 110, MAGOKDONG-RO, GANGSEO-GU, SEOUL, KOREA
Initial Date of Registration : 2006-01-31
Latest Date of Registration : 2019-09-17

Registration Number : 303MF10076
Registrant's Address : 110, MAGOKDONG-RO, GANGSEO-GU, SEOUL, KOREA
Initial Date of Registration : 2021-05-10
Latest Date of Registration : 2021-05-10

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Date of Issue : 2025-06-30
Valid Till : 2028-06-22
Written Confirmation Number : WC-014
Address of the Firm : Situated at Chemical Division, Mekaguda (Village), Nandigama (Mandal), Ranga Red...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Otran Korea Co., Ltd.
Registration Date : 2025-04-30
Registration Number : 20250430-210-J-1853
Manufacturer Name : BrightGene Pharmaceutical Co...
Manufacturer Address : Building C25-C28, No.218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123,...

Registrant Name : Hwail Pharmaceutical Co., Ltd.
Registration Date : 2020-07-14
Registration Number : 20200714-210-J-587
Manufacturer Name : BrightGene Pharmaceutical Co...
Manufacturer Address : 57, Jaegyegongdan 3-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Building C25-C28, No...

Registrant Name : Kolon Life Science Co., Ltd.
Registration Date : 2025-11-28
Registration Number : 20251128-210-J-2072
Manufacturer Name : Kolon Life Science Co., Ltd.
Manufacturer Address : 54, Gippdosi 1-ro, Daesowon-myeon, Chungju-si, Chungcheongbuk-do

Registrant Name : Tanabe Pharma Korea Co., Ltd.
Registration Date : 2022-01-21
Registration Number : 20220121-210-J-1219
Manufacturer Name : Mitsubishi Tanabe Pharma Fac...
Manufacturer Address : 7473-2, Ooaza Onoda, SanyoOnoda,Yamaguchi, 756-0054, Japan

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Apino Pharma prides itself on being an innovation-driven company that strives to continuously improve its products and services. Our dedicated innovation team collaborates with the...

About the Company : BrightGene Bio-Medical Technology Co., Ltd. is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special gener...

About the Company : Curia is a global contract research, development and manufacturing organization (CDMO), offering products and services across the drug development spectrum to help our partners tur...

About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...

About the Company : Hameln rds s.r.o. located in Slovakia, Europe, part of the European Union, is a well-known pharmaceutical company producing APIs and services for the healthcare industry, with focu...

About the Company : Jiangsu Lianhuan Pharmaceutical Co., Ltd. was founded in 2000. It is a state-controlled competitive listed company. Its predecessor was Yangzhou Pharmaceutical Factory, which was e...

About the Company : Kivipharm was established in 1973. After 40 years development, this company become one of the leading manufacturer of aseptic pharmaceutical products in china. Our products was exp...

About the Company : Sailong Pharmaceutical Group Co., Ltd. ("Salon Pharmaceutical" for short) was established in 2002. It is a high-tech enterprise integrating drug research and development, productio...

About the Company : SMS Lifesciences is a global player in APIs/Intermediates manufacturing having a strong research and manufacturing team supported by state of the art facilities. What started off a...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Ethyl (2R,4R)-4-methyl-2-piperidinecarboxylate
CAS Number : 74892-82-3
End Use API : Argatroban
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
(2R,4R)-4-Methylpiperidine-2-carboxylic acid
CAS Number : 74892-81-2
End Use API : Argatroban
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
3-Methyl-8-quinolinesulphonyl chloride
CAS Number : 74863-82-4
End Use API : Argatroban
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
27 Apr 2022
Reply
15 Apr 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
90
PharmaCompass offers a list of Argatroban API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Argatroban manufacturer or Argatroban supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Argatroban manufacturer or Argatroban supplier.
PharmaCompass also assists you with knowing the Argatroban API Price utilized in the formulation of products. Argatroban API Price is not always fixed or binding as the Argatroban Price is obtained through a variety of data sources. The Argatroban Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Argatroban manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Argatroban, including repackagers and relabelers. The FDA regulates Argatroban manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Argatroban API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Argatroban manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Argatroban supplier is an individual or a company that provides Argatroban active pharmaceutical ingredient (API) or Argatroban finished formulations upon request. The Argatroban suppliers may include Argatroban API manufacturers, exporters, distributors and traders.
click here to find a list of Argatroban suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Argatroban DMF (Drug Master File) is a document detailing the whole manufacturing process of Argatroban active pharmaceutical ingredient (API) in detail. Different forms of Argatroban DMFs exist exist since differing nations have different regulations, such as Argatroban USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Argatroban DMF submitted to regulatory agencies in the US is known as a USDMF. Argatroban USDMF includes data on Argatroban's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Argatroban USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Argatroban suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Argatroban Drug Master File in Japan (Argatroban JDMF) empowers Argatroban API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Argatroban JDMF during the approval evaluation for pharmaceutical products. At the time of Argatroban JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Argatroban suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Argatroban Drug Master File in Korea (Argatroban KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Argatroban. The MFDS reviews the Argatroban KDMF as part of the drug registration process and uses the information provided in the Argatroban KDMF to evaluate the safety and efficacy of the drug.
After submitting a Argatroban KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Argatroban API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Argatroban suppliers with KDMF on PharmaCompass.
A Argatroban written confirmation (Argatroban WC) is an official document issued by a regulatory agency to a Argatroban manufacturer, verifying that the manufacturing facility of a Argatroban active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Argatroban APIs or Argatroban finished pharmaceutical products to another nation, regulatory agencies frequently require a Argatroban WC (written confirmation) as part of the regulatory process.
click here to find a list of Argatroban suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Argatroban as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Argatroban API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Argatroban as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Argatroban and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Argatroban NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Argatroban suppliers with NDC on PharmaCompass.
Argatroban Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Argatroban GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Argatroban GMP manufacturer or Argatroban GMP API supplier for your needs.
A Argatroban CoA (Certificate of Analysis) is a formal document that attests to Argatroban's compliance with Argatroban specifications and serves as a tool for batch-level quality control.
Argatroban CoA mostly includes findings from lab analyses of a specific batch. For each Argatroban CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Argatroban may be tested according to a variety of international standards, such as European Pharmacopoeia (Argatroban EP), Argatroban JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Argatroban USP).